Spots Global Cancer Trial Database for A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Official Title: A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Study ID: NCT01778439
Conditions
Interventions
Study Description
Brief Summary: This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory solid tumors. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California, San Francisco/Helen Diller Cancer Institute, San Francisco, California, United States
University of Colorado Denver -RCI-South Tower, Aurora, Colorado, United States
Karmanos Cancer Institute (KCI), Detroit, Michigan, United States
Wayne State University/Oncology Karmanos Cancer Institute, Detroit, Michigan, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
